Precision Pharmacology in Incretin-Based Therapies | Dr. Aaron Novikoff | EASD Congress 2026

Dr. Aaron Novikoff talks with medical editor Birgit Schulze about new approaches in incretin pharmacology. The interview was recorded at the 2026 EASD Congress in Milan, where Novikoff received the Rising Star Award. The discussion focuses on drugs that target multiple receptors at the same time, and on how the efficacy and tolerability of incretin therapies might be more precisely influenced. It also explores differences in treatment response, individual biological factors and potential approaches to more personalized treatment. 🔍 What to expect in this video: – Why patients respond differently to incretin therapies – How polyagonists target multiple receptors, including GLP-1, GIP, glucagon and amylin – How targeted receptor activation could affect side effects – The role of dosage forms and dosing frequency in clinical practice – Why treatment effects can differ between patient groups – What researchers are learning about appetite regulation, glucose metabolism and reward systems – New drug concepts and personalized treatment approaches under discussion ⏱ Timestamps: 00:00 Introduction: Rising Star Award and research focus 00:27 New strategies in incretin pharmacology 01:42 Differences in efficacy and tolerability 02:00 Targeting multiple receptors 02:53 Polyagonists, dosage forms and treatment adherence 04:23 Differences in treatment response across patient groups 05:24 Individual biology, appetite and glucose metabolism 06:51 Reward systems and potential long-term effects 07:50 Which developments could change pharmacotherapy? 08:21 New drug concepts and preserving muscle mass 09:05 Peptide conjugates and a potential “toolkit” for therapies 10:01 Personalized treatment and lower-dose strategies The interview offers insights into current research—and highlights the questions that remain about the targeted and individualized use of incretin therapies. 🔔 Subscribe to MGB Medizin for more expert interviews in diabetology and medicine: 👉 / @mgbmedizin More expert content for physicians: https://www.mgb-medizin.de #IncretinTherapy #PrecisionMedicine #Polyagonists #GLP1 #Obesity #Diabetes #Pharmacology #EASD2026 #AaronNovikoff